Abstract: The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.
Type:
Grant
Filed:
April 10, 2008
Date of Patent:
February 20, 2018
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Arturo Reyes, Adrian Hill, Geraldine O'Hara, Stefano Colloca, Riccardo Cortese
Patent number: 9879054
Abstract: The present invention provides novel sequences encoding Staphylococcus pseudintermedius proteins/nucleic acids potentially useful in the treatment and/or prevention of canine disorders. In particular, the various protein and/or nucleic acid sequences described herein may find application as vaccines for use in treating and/or preventing a variety of canine diseases and/or conditions caused or contributed to by Staphylococcus pseudintermedius.
Type:
Grant
Filed:
April 13, 2012
Date of Patent:
January 30, 2018
Assignee:
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
Inventors:
Jeanette Bannoehr, Ross J. Fitzgerald, Nouri L. Ben Zakour
Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
November 21, 2017
Assignee:
Infectious Disease Research Institute
Inventors:
Steven G. Reed, Rhea N. Coler, Gregory C. Ireton
Abstract: The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd.
Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
Abstract: Provided are a human-derived insect-resistant gene having a nucleotide sequence represented by SEQ ID NO.1, and an anti-Cry1B toxin idiotype single-chain antibody encoded by said human-derived insect-resistant gene and having an amino acid sequence represented by SEQ ID NO.2. The idiotype single-chain antibody is a ?-type and has insecticidal activity, and after expression by the prokaryotic system, the primary culture thereof has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
September 26, 2017
Assignee:
JIANGSU ACADEMY OF AGRICULTURAL SCIENCES INSTITUTE OF FOOD SAFETY AND MONITORING TECHNOLOGY
Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.
Type:
Grant
Filed:
October 25, 2011
Date of Patent:
September 26, 2017
Assignee:
National Research Council of Canada
Inventors:
Greg Hussack, Mehdi Nath Arbabi-Ghahroudi, Roger Mackenzie, Jamshid Tanha
Abstract: The present invention discloses novel isolates of Neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against Potomac Horse Fever.
Type:
Grant
Filed:
April 8, 2016
Date of Patent:
September 19, 2017
Assignee:
Intervet Inc.
Inventors:
Lisa Purtle, Mark Mellencamp, Wendy Vaala
Abstract: An anthropogenic pest-resistant gene having a nucleotide sequence as represented by SEQ IN NO. 1, and, an anti-Cry1Ab toxin idiotypic single-chain antibody encoded by the anthropogenic pest-resistant gene and having a nucleotide sequence as represented by SEQ IN NO. 2.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
September 5, 2017
Assignee:
JIANGSU ACADEMY OF AGRICULTURAL SCIENCES INSTITUTE OF FOOD SAFETY AND MONITORING TECHNOLOGY
Abstract: The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE(A)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described. A method of producing the said protein or truncated fragments thereof recombinantly is also disclosed.
Abstract: Method and compositions using transition metal salts and/or ammonium chloride to liberate toxins and other molecules from cyanobacteria, useful for assaying for total cyanobacterial toxins in lakes, reservoirs and other waters.
Abstract: The present invention discloses a human-derived insecticidal gene and insecticidal peptide encoded by the same and application thereof. The nucleotide sequence of the human-derived insecticidal gene is as represented by SEQ ID NO.1. The amino acid sequence of the insecticidal peptide encoded by this gene is as represented by SEQ ID NO.2. The insecticidal peptide may be expressed through prokaryotic system. The primary culture has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV. It is obtained without animal immunization and has a short production cycle and a small amino acid sequence. It is suitable for in vitro mass production and may lower the safety risks resulting from wide use of existing Bt toxins and even might substitute Bt to biologically control agricultural pests in the future. It has important scientific and practical significance to reducing the use of insecticides.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
August 8, 2017
Assignee:
JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with Mtb, preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the inhibition, prevention and/or treatment of tuberculosis are also disclosed.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
August 1, 2017
Assignees:
Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs
Inventors:
David M. Lewinsohn, Deborah A. Lewinsohn
Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
Type:
Grant
Filed:
December 21, 2015
Date of Patent:
June 13, 2017
Assignee:
Battelle Energy Alliance, LLC
Inventors:
David N Thompson, William A Apel, Vicki S Thompson, David W Reed, Jeffrey A Lacey
Abstract: Biosensors are made by attaching covalently or non-covalently at least one reporter group to one or more specific positions of a bacterial periplasmic binding protein (bPBP). Upon binding of ligand to the biosensor, there is a change in the signal transduced by the reporter group.
Abstract: The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.
Type:
Grant
Filed:
January 13, 2014
Date of Patent:
February 14, 2017
Assignee:
SANOFI PASTEUR VAXDESIGN CORPORATION
Inventors:
Ayesha Mahmood, Anatoly Kachurin, William Warren, Russell Higbee
Abstract: Specific DNA sequences for binding various foodborne and waterborne pathogens and biotoxins are described. Each of these sequences can function in varying assay and sensor formats with varying degrees of success.
Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.
Type:
Grant
Filed:
March 20, 2014
Date of Patent:
January 31, 2017
Assignee:
The United States of America, as Represented by the Secretary of Agriculture
Inventors:
Felicito Guerrero, Adalberto A. Perez de Leon
Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran Borrelia infections.
Type:
Grant
Filed:
August 1, 2014
Date of Patent:
January 31, 2017
Assignee:
Virgina Commonwealth University
Inventors:
Richard T. Marconi, Christopher Earnhart
Abstract: This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp.